Leonard G. Gomella, MD, from the Kimmel Cancer Center, discusses the utilization of circulating tumor cells in patients with solid tumors.
Leonard G. Gomella, MD, Chair of Urology at Thomas Jefferson University Hospital and Director of Clinical Affairs at the Kimmel Cancer Center, discusses the utilization of circulating tumor cells (CTCs) in patients with solid tumors.
A major challenge currently facing the use of CTCs is a lack of adequate assays to accurately detect low levels of cells. However, Gomella adds, techniques and gradient technologies are currently being assessed to alleviate sensitivity concerns with very low cell counts.
An exciting area of research involves capturing CTC and interrogating them for genetic alterations, Gomella notes. In the future, this area of research will continue to be explored further.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More